Total | Persistent oligoarthritis | Extended oligoarthritis | RF-positive polyarthritis | RF-negative polyarthritis | Systemic | Enthesitis-related arthritis | Psoriatic arthritis | Undifferentiated arthritis | |
Patients (N/%) | 585 (100) | 105 (17.9) | 78 (13.3) | 68 (11.6) | 99 (16.9) | 56 (9.6) | 110 (18.8) | 19 (3.3) | 54 (9.2) |
Female (N/%) | 385 (65.8) | 77 (73.3) | 55 (70.5) | 62 (91.2) | 66 (68.0) | 33 (58.9) | 41 (38,0) | 14 (73.7) | 34 (63.0) |
Age at disease onset (years; median(Q1; Q3)) | 9.9 (5.1; 13.7) | 7.6 (2.9; 11) | 5.2 (2.1; 9.4) | 11.2 (7.8; 13.4) | 8.7 (3.9; 13) | 6.9 (4.1; 11.9) | 12.5 (10.1; 15) | 10.4 (6.4; 13.4) | 13.9 (11.5; 15) |
Age at diagnosis (years; median(Q1; Q3)) | 12 (6.9; 16) | 8.3 (3.5; 11.9) | 7 (3; 13.8) | 12.2 (9.1; 15.2) | 11.8 (7.2; 16) | 7.1 (4.6; 14.3) | 15.1 (12.7; 17) | 12.8 (8.5; 15.5) | 18 (14.7; 25.4) |
Age at the time of last visit (years; median(Q1; Q3)) | 28.6 (21.8; 38.6) | 22.3 (20.2; 29.1) | 25.95 (21.1; 36.2) | 35.3 (24.9; 42.7) | 29.2 (22.3; 38.4) | 30.15 (24.45; 38.3) | 28.2 (21.7; 39.5) | 24.5 (20.6; 32.9) | 47.4 (37.7; 53.9) |
Disease duration (years; median(Q1; Q3)) | 20.2 (12.8; 29.6) | 16.6 (12.43; 23) | 20 (16.5; 27.9) | 24.1 (12.8; 33.6) | 21.5 (12.9; 30.7) | 22.7 (14.8; 30.2) | 15.8 (9.4; 26.7) | 14.9 (9.1; 24.2) | 34.3 (25.4; 43.7) |
ANA + (N/%) | 141 (33.6 | 52 (54.7) | 28 (45.2) | 16 (31.4) | 18 (23.7) | 6 (15.4) | 11 (18.3) | 7 (41.2) | 3 (17.7) |
RF + (N/%) | 81 (17.3) | 3 (3.5) | 7 (10) | 58 (92.1) | 0 (0) | 0 (0) | 0 (0) | 2 (11.8) | 11 (32.3) |
ACPA + (N/%) | 52 (19.6) | 2 (5) | 4 (12.1) | 37 (72.5) | 3 (5) | 0 (0) | 0 (0) | 1 (10) | 5 (22.7) |
HLA B27 + (N/%) | 103 (26.5 | 3 (5.9) | 4 (8.5) | 1 (1,9) | 3 (5.3) | 1 (3) | 81 (81.8) | 3 (21.4) | 7 (19.4) |
Years of education (median(Q1; Q3)) | 12 (9; 15) | 12 (11.5; 15.5) | 12 (9; 12) | 12 (12; 15) | 12 (9; 12) | 12 (11; 17) | 12 (9; 15) | 12 (6; 16) | 12 (9; 15) |
Professional situation | |||||||||
Employed | 266 (78.7%) | 37 (94.9%) | 29 (76.3%) | 34 (77.3%) | 51 (77.3%) | 24 (88.9%) | 55 (73.3%) | 6 (66.7%) | 28 (73.7%) |
Unemployed | 30 (8.8%) | 2 (5.1%) | 2 (5.3%) | 3 (6.8%) | 8 (12.1%) | 2 (7.4%) | 10 (13.3%) | 2 (22.2%) | 1 (2.6%) |
Retired | 13 (3.8%) | 0 (0%) | 1 (2.6%) | 4 (9.1%) | 3 (4.5%) | 0 (0%) | 2 (2.7%) | 0 (0%) | 3 (7.9%) |
Retired due to JIA disability | 29 (8.6%) | 0 (0%) | 6 (15.8%) | 3 (6.8%) | 4 (6.1%) | 1 (3.7%) | 8 (10.7%) | 1 (11.1%) | 6 (15.8%) |
Disease activity | |||||||||
Active (N/%) | 171 (37.7) | 20 (25) | 23 (38.3) | 23 (51.1) | 30 (40.5) | 26 (47.3) | 28 (34.2) | 2 (16.7) | 19 (44.2) |
Inactive (N/%) | 282 (62.3) | 60 (75) | 37 (61.7) | 22 (48.9) | 44 (59.5) | 29 (52.7) | 54 (65.9) | 10 (83.3) | 24 (55.8) |
JADI-A (median(Q1; Q3)) | 0 (0; 6) | 0 (0; 0) | 1 (0; 7) | 2.5 (0; 24) | 4 (0; 13) | 6 (0; 20) | 0 (0; 0) | 0 (0; 0) | 29 (29; 29) |
JADI-E (median(Q1; Q3)) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 1) | 0 (0; 2) | 0 (0; 0) | 0 (0; 0) | 4 (4; 4) |
Past treatment | |||||||||
Corticosteroids (N/%) | 233 (39.8) | 21 (20.2) | 23 (29.5) | 54 (79.4) | 39 (39.4) | 35 (62.5) | 28 (26.2) | 4 (21.1) | 27 (55.1) |
Synthetic DMARDs (N/%) | 469 (80.2) | 74 (71.2) | 65 (83.3) | 64 (94.1) | 88 (88.9) | 46 (82.1) | 67 (62.6) | 17 (89.5) | 43 (87.8) |
Biological DMARDs (N/%) | 269 (46) | 19 (18.3) | 32 (41) | 47 (69.1) | 38 (38.4) | 26 (46.4) | 56 (52.3) | 8 (42.1) | 39 (79.6) |
Current treatment | |||||||||
Corticosteroids (N/%) | 135 (23.1) | 8 (7.7) | 13 (16.7) | 34 (50) | 25 (25.3) | 20 (35.7) | 11 (10.3) | 2 (10.5) | 21 (42.9) |
Synthetic DMARDs (N/%) | 302 (51.6) | 47 (45.2) | 43 (55.1) | 43 (63.2) | 56 (56.6) | 26 (46.4) | 37 (34.6) | 10 (52.6) | 35 (71.4) |
Biological DMARDs (N/%) | 208 (35.9) | 17 (16.4) | 23 (29.5) | 38 (55.9) | 29 (29.3) | 19 (33.9) | 44 (41.1) | 6 (31.6) | 32 (65.3) |
Sample size is not constant due to missing data:.
Age at diagnosis: total n=553; persistent oligoarthritis n=100; extended oligoarthritis n=74; RF positive polyarthritis n=65; RF negative polyarthritis n=91; systemic n=51 enthesitis-related arthritis n=101; psoriatic arthritis n=18; undifferentiated arthritis n=49.
ANA: total n=419; persistent oligoarthritis n=95; extended oligoarthritis n=62; RF positive polyarthritis n=51; RF negative polyarthritis n=76;systemic n=39; enthesitis-related arthritis n=60; psoriatic arthritis n=17; undifferentiated arthritis n=19
RF: total n=469; persistent oligoarthritis n=86; extended oligoarthritis n=70; RF positive polyarthritis n=63; RF negative polyarthritis n=93; systemic n=41; enthesitis-related arthritis n=65; psoriatic arthritis n=17; undifferentiated arthritis n=34
ACPA: total n=264; persistent oligoarthritis n=40; extended oligoarthritis n=33; RF positive polyarthritis n=51; RF negative polyarthritis n=60; systemic n=21; enthesitis-related arthritis n=27; psoriatic arthritis n=10; undifferentiated arthritis n=22
HLA B27: total n=264; persistent oligoarthritis n=40; extended oligoarthritis n=33; RF positive polyarthritis n=51; RF negative polyarthritis n=60; systemic n=21; enthesitis-related arthritis n=27; psoriatic arthritis n=10; undifferentiated arthritis n=22.
Years of education: total n=317; persistent oligoarthritis n=36; extended oligoarthritis n=39; RF positive polyarthritis n=37; RF negative polyarthritis n=63; systemic n=27; enthesitis-related arthritis n=70; psoriatic arthritis n=10; undifferentiated arthritis n=33.
Professional situation: total n=338; persistent oligoarthritis n=39; extended oligoarthritis n=38; RF positive polyarthritis n=44; RF negative polyarthritis n=66; systemic n=27; enthesitis-related arthritis n=75; psoriatic arthritis n=10; undifferentiated arthritis n=38.
Disease activity: total n=453; persistent oligoarthritis n=80; extended oligoarthritis n=60; RF positive polyarthritis n=45; RF negative polyarthritis n=74; systemic n=55; enthesitis-related arthritis n=82; psoriatic arthritis n=12; undifferentiated arthritis n=43.
JADI-A/JADI-E: total n=190/186; persistent oligoarthritis n=36/33; extended oligoarthritis n=32/29; RF positive polyarthritis n=22/24; RF negative polyarthritis n=39/38; systemic n=21/20; enthesitis-related arthritis n=33/35; psoriatic arthritis n=6/6; undifferentiated arthritis n=1/1.
.ACPA, anti-citrullinated protein antibodies; ANA, antinuclear antibodies; DMARD, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; JADI-A, Juvenile Arthritis Damage Index—articular; JADI-E, Juvenile Arthritis Damage Index—extra-articular; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor.